Treatment of epithelial ovarian cancer

Review describes maintenance therapy with poly ADP-ribose polymerase inhibitors, bevacizumab, and/or drugs targeting homologous recombination deficiency; stating they are becoming more widely used and advancement of immunotherapy is further revolutionising treatment targets.

British Medical Journal